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Simple Summary: DDX11, a helicase involved in sister chromatid cohesion, was identified as a
significant biomarker of aggressive renal cell carcinoma (RCC) in our previous studies. In this
study, we evaluated the molecular pathways through which DDX11 is involved in RCC cell survival.
Furthermore, we assessed the sensitivity of poly (ADP-ribose) polymerase (PARP) inhibitors, which
have not been used in RCC treatment, in association with DDX11 expression. DDX11-deficient
RCC inhibited RCC proliferation, caused defects in segregation, and increased apoptosis. DDX11-
deficient RCC was associated with increased sensitivity to PARP inhibition. DDX11 could be a novel
therapeutic and prognostic biomarker for RCC patients, and this study is the first to suggest the use
of PARP inhibitors in DDX11-deficient RCC patients.
Abstract: Genes associated with the DEAD-box helicase DDX11 are significant biomarkers of aggres-
sive renal cell carcinoma (RCC), but their molecular function is poorly understood. We analyzed the
molecular pathways through which DDX11 is involved in RCC cell survival and poly (ADP-ribose)
polymerase (PARP) inhibitor sensitivity. Immunohistochemistry and immunoblotting determined
DDX11 expression in normal kidney tissues, benign renal tumors, and RCC tissues and cell lines.
Quantitative polymerase chain reaction validated the downregulation of DDX11 in response to
transfection with DDX11-specific small interfering RNA. Proliferation analysis and apoptosis assays
were performed to determine the impact of DDX11 knockdown on RCC cells, and the relevant
effects of sunitinib, olaparib, and sunitinib plus olaparib were evaluated. DDX11 was upregulated in
high-grade, advanced RCC compared to low-grade, localized RCC, and DDX11 was not expressed
in normal kidney tissues or benign renal tumors. DDX11 knockdown resulted in the inhibition
of RCC cell proliferation, segregation defects, and rapid apoptosis. DDX11-deficient RCC cells
exhibited significantly increased sensitivity to olaparib compared to sunitinib alone or sunitinib plus
olaparib combination treatments. Moreover, DDX11 could determine PARP inhibitor sensitivity in
RCC. DDX11 could serve as a novel therapeutic biomarker for RCC patients who are refractory to
conventional targeted therapies and immunotherapies.
Keywords: renal cell carcinoma; DDX11; PARP inhibitor; olaparib; sunitinib; 786-O
1. Introduction
The understanding of the biology of renal cell carcinoma (RCC), especially the per-
turbed pathways that lead to the development and growth of tumors and their multiple
subtypes with distinct molecular abnormalities, has been steadily improving [1,2]. Some
RCC patients (30%) present with metastatic disease at the time of initial diagnosis, and
almost 30% of the patients with localized RCC develop recurrent disease during follow-up,
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which requires systemic therapy [3]. Treatments for advanced RCC have become markedly
advanced over the past 30 years due to significant improvements in our understanding
of this cancer [2]. Multiple therapeutic agents with varying mechanisms are available,
and combinatorial therapy using agents with different mechanisms is now being explored.
Therefore, it is crucial to provide patients with the most effective therapy and promote their
quality of life [2,4]. Appropriate therapeutic effects of a combinatorial regimen along with
dosage optimization will need to be ascertained to avoid treatment discontinuation due to
intolerable toxicity and ensure that a marked therapeutic outcome can be achieved [5].
Although our understanding of the genomic characterization of RCC has dramatically
improved, molecular profiling of RCC has not been conducted in routine clinical care,
especially for selecting targeted therapies for advanced RCC [6]. None of the clinically
available biomarkers can delineate advanced RCC patients who stand to benefit from
specific molecule-targeted agents and individualized clinical management strategies [6,7].
In line with our long-term effort to identify genes associated with the aggressiveness
of clear cell RCC (ccRCC) [8–10], we recently profiled archived formalin-fixed paraffin-
embedded tissue samples of clinical T1 stage ccRCC [9]. The data from the total RNA
sequencing of 24 ccRCC patients (12 patients with, and 12 patients without, aggressive
characteristics) revealed 10 genes with the highest upregulation or downregulation in
aggressive ccRCC. Among these 10 genes, DDX11 was significantly upregulated in ag-
gressive ccRCC and was associated with low cancer-specific survival and high recurrence
rates [9]. Moreover, a prospective validation study (NCT03694912) that employed quantita-
tive reverse transcription polymerase chain reaction (qRT-PCR) for investigating the gene
expression profile of frozen tissues revealed DDX11 to be a significant predictor of ccRCC
aggressiveness [10].
DDX11, a member of the DEAD (Asp-Glu-Ala-Asp)/DEAH (Asp-Glu-Ala-His) box
family of helicases comprising more than 40 members, is essential for the cohesion of chro-
mosome arms and centromeres [11]. When DDX11 is depleted, mitotic failure occurs due
to replicated chromosomes failing to segregate after prometaphase arrest [11]. DDX11 has
been shown to be associated with melanomas and lung cancer [12,13]; however, no studies
have been performed regarding its association with ccRCC. Furthermore, because the use
of poly (ADP-ribose) polymerase (PARP) inhibitors in RCC is not clinically indicated [2], it
would be helpful to expand the usage of PARP inhibitors in certain RCC patients in whom
the benefits would be promising.
Thus, we aimed to elucidate the molecular pathways through which DDX11 is in-
volved in RCC cell survival and PARP inhibitor sensitivity in RCC.
2. Methods
2.1. RCC Cell Lines and Tissues
The human RCC cell lines 786-O (cat# CRL-1932), Caki-1 (cat# HTB-46), A-498 (cat#
HTB-44), and ACHN (cat# CRL-1611), and the human proximal tubular cell line, HK-2,
representing normal kidney cells (cat# CRL-2190), were purchased from the American
Type Culture Collection (Manassas, VA, USA). These cells were cultured in Roswell Park
Memorial Institute (RPMI) or Eagle’s Minimum Essential Medium (EMEM) medium
supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Waltham,
MA, USA) and 1% penicillin-streptomycin (Sigma-Aldrich, St. Louis, MO, USA) at 37 ◦C in
a humidified atmosphere containing 5% CO2.
Standard immunohistochemistry analysis to assess the expression of DDX11 was per-
formed using a mouse monoclonal antibody against human DDX11 (Sigma-Aldrich) in 6 cry-
opreserved human tissue samples from nephrectomy specimens (where none of the patients
received preoperative chemotherapy or radiation prior to surgical excision). The samples
represented normal kidney tissues, benign renal tumors (angiomyolipoma and oncocytoma),
localized low-grade ccRCC, localized high-grade ccRCC, and advanced high-grade ccRCC.
All DDX11 antibody-probed tissue sections were counterstained with hematoxylin.
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We obtained ethical approval from the Institutional Review Board of the Yonsei
University Health System (project no. 4-2013-0742) before procuring the tissue. A senior
urologic pathologist with extensive experience in renal pathology (N.H.C.) evaluated the
staining. Grading was based on the grading system recommended by the World Health
Organization (WHO)/International Society of Urological Pathology (ISUP) [14]. Low-grade
ccRCC constitutes Fuhrman or WHO/ISUP grades I and II, whereas high-grade ccRCC
constitutes grades III and IV.
2.2. Immunoblotting and Immunofluorescence
Cells were lysed in radioimmunoprecipitation assay lysis buffer (Cell Signaling Tech-
nology, Beverly, MA, USA) to prepare total protein, and equal amounts of the protein lysate
(30 µg/sample) were separated on sodium dodecyl sulfate-polyacrylamide gels and trans-
ferred onto a nylon membrane. The membranes were then probed with primary antibodies
against human DDX11 (MyBioSource, San Diego, CA, USA) or β-actin (Santa Cruz Biotech-
nology, Dallas, TX, USA), followed by incubation with horseradish peroxidase-conjugated
secondary antibody (Cell Signaling Technology). Protein bands were visualized using the
Amersham ECL Prime Western Blotting Detection System (GE Healthcare, Amersham, UK).
For immunofluorescence staining, cells were plated on Lab-Tek chamber slides (NUNC,
Naperville, IL, USA) and received the desired treatment. At the end of the treatment,
RCC cells were fixed with 4% paraformaldehyde and incubated with 0.5% Triton X-100
(Sigma-Aldrich) for 5 min. Non-specific proteins were then blocked with 10% normal
serum with 0.1% Triton X-100 at room temperature for 1 h and stained with the primary
antibodies against human DDX11 (Sigma-Aldrich) or PARP (Cell Signaling Technology)
that could detect total full-length PARP-1. After washing, slides were incubated with Alexa
Fluor 555- or fluorescein-labeled secondary antibodies (Vector Laboratories, Burlingame,
CA, USA) and mounted with VECTASHIELD® Mounting Medium (Vector Laboratories).
The immunofluorescence images were captured using a Zeiss LSM700 confocal microscope
(Carl Zeiss Microscopy GmbH, Jena, Germany) [12].
2.3. DDX11 Small Interfering (si) RNA Transfection
RCC cells were transfected with 5 nM of a custom-synthesized Cy5-conjugated DDX11
siRNA (Dharmacon, Lafayette, CO, USA) for 24 h and fixed with 4% paraformaldehyde,
counterstained with DAPI (Invitrogen, Thermo Fisher Scientific, Waltham, MA, USA),
and imaged. The Cy5-conjugated DDX11 siRNA was designed to target the 5′-CCU GUG
UCU GUC UUC CUG CGA A-3′ sequence—a 25 bp region determined using the Basic
Local Alignment Search Tool [12]—in exon 3 of human DDX11 located on chromosome
12p11 [15]. It was conjugated to the fluorophore Cy5 via a Label IT siRNA Tracker Intracel-
lular Localization Kit (Mirus Bio, Madison, WI, USA). Dual color images were processed
using Zeiss LSM700 (Carl Zeiss Microscopy GmbH). RCC cells were transfected with the
single DDX11 siRNA (Dharmacon) or a control ON-TARGETplus Non-targeting siRNA
Pool (Dharmacon) using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen). In
order to rule out possible off-target effects, SMARTpool ON-TARGETplus DDX11 siRNA
(Dharmacon) and Silencer Select DDX11 siRNA (Thermo Fisher Scientific) were used.
The results were the same for all 3 different DDX11-targeting siRNAs (Supplementary
Figure S1).
2.4. qRT-PCR
Total RNA was prepared from DDX11- and control siRNA-transfected RCC cells using
the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). The RNase-Free DNase Set (Qiagen) was
used to remove genomic DNA contamination from the prepared RNA. Complementary
DNA (cDNA) was synthesized using Maxime RT PreMix (iNtRON Biotechnology, Korea)
from 1 µg of RNA. For qPCR, primers spanning the human DDX11 exon boundary 20–22
(Bioneer Corporation, Daejeon, Korea) that generated an 88 bp amplicon were used. Human
glyceraldehyde 3-phosphate dehydrogenase primers served as the internal control, and
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primers against the same were synthesized by Bioneer Corporation. qPCR was performed
on a StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) using
Power SYBR Green Master Mix (Thermo Fisher Scientific), and involved 40 qPCR cycles
(15 s at 95 ◦C, 30 s at 58 ◦C, 1 min at 72 ◦C); data were analyzed using the 2−∆∆Ct method.
2.5. Cell Proliferation and Apoptosis Analysis
RCC cell proliferation was determined using the Cell Counting Kit-8 (CCK-8; Dojindo
Laboratories, Kumamoto, Japan) according to the manufacturer’s instructions. Briefly,
cells were seeded in 96-well plates at a density of 2000–5000 cells per well and transiently
transfected. DDX11- as well as control siRNA-transfected cells and cells that had received
only Lipofectamine RNAiMAX (Invitrogen) were analyzed in triplicate at 24, 48, and 72 h.
Furthermore, DDX11- as well as control siRNA-transfected cells were treated with the
desired concentrations of the inhibitors (5 µM sunitinib and 10 µM olaparib (Selleckchem,
Houston, TX, USA)). To properly examine the effects of PARP inhibitors, sensitivity assays
at different drug concentrations were performed [16]. Because cell viability was signifi-
cantly different in concentrations higher than 10 µM olaparib (Supplementary Figure S2A),
we decided to use the concentration of 10 µM. For veliparib, the concentration of 100 µM
was used because cell viability was significantly different in concentrations higher than
100 µM veliparib (Supplementary Figure S2B). Each plate was incubated for 24, 48, or
72 h, as indicated. At the end of the experiment, 10 µL of CCK-8 solution was added and
incubated for 4 h at 37 ◦C. Absorbance was detected at 450 nm using a VersaMax Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA). For the detection of apoptosis using
immunofluorescence, DDX11- as well as control siRNA-transfected RCC cells were fixed,
permeabilized, labeled using the In Situ Cell Death Detection Kit, TMR red (Roche Applied
Science, Indianapolis, IN, USA), counterstained with fluorescent DAPI, and imaged.
3. Results
3.1. DDX11 Expression in Normal Kidney Tissues, Benign Renal Tumors, and RCC Tissues and
Cell Lines
Immunohistochemistry analysis of cryopreserved tissue sections prepared from nor-
mal kidney, benign renal tumors (angiomyolipoma and oncocytoma), localized low-grade
ccRCC, localized high-grade ccRCC, and advanced high-grade ccRCC using an antibody
against human DDX11 revealed strong expression of DDX11 in advanced and high-grade
ccRCC, whereas weak DDX11 expression was noted in localized and low-grade ccRCC
(Figure 1A). In contrast, DDX11 expression was not detected in normal kidney tissues or
benign renal tumors (Figure 1A).
Subsequent immunoblot analysis revealed strong DDX11 expression in advanced and
high-grade ccRCC, but no DDX11 expression was observed in normal kidney tissues or
benign renal tumors (Figure 1B).
Immunoblotting revealed that the expression of DDX11 was higher in 786-O cells
(RCC) than in other RCC cell lines or HK-2 cells (human proximal tubular cells) (Figure 1C).
Using 786-O cells, which exhibited clearly detectable expression of the 109-kD DDX11
protein, we performed additional DDX11-based immunofluorescence analysis, as DDX11
has been reported to be dynamically localized during mitosis [11]. With no pretreatment
for enriching cells in mitosis, DDX11 antibody staining of 786-O cells demonstrated the ex-
pression and localization of DDX11 during interphase (Figure 2, lane a) and the subsequent
stages of mitosis (Figure 2, lanes b–e).
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Figure 1. DDX11 expression in normal kidney tissues, benign renal tumors, and renal cell carcinoma
(RCC) cell lines and tissues. (A) Cryopreserved tissue sections representing normal kidney tissues,
benign renal tumors (angiomyolipoma and oncocytoma), localized low-grade clear cell RCC (ccRCC),
localized high-grade ccRCC, and advanced high-grade ccRCC were stained with an antibody against
human DDX11 and counterstained with hematoxylin. Images were captured at 200 ×magnification,
Scale bar: 200 µm. (B) Immunoblot representing the expression of DDX11 in normal kidney tissues,
benign renal tumors, and ccRCC (localized low- and high-grade ccRCC and advanced high-grade
ccRCC) tissues. (C) Immunoblot representing the expression of DDX11 in RCC cells (786-O, Caki-1,
A-498, and ACHN) and the human proximal tubular cell line (HK-2). β-actin was used as the internal
control. Original Western Blots can be found in Figure S5.
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Figure 2. Immunofluorescence analysis representing DDX11 expression in renal cell carcinoma cells. DDX11 expression in
786-O cells during interphase (a), prophase (b), metaphase (c), telophase (d), and late telophase (e); DDX11 (pseudocolored
red), nuclei (pseudocolored blue; DAPI), Scale bar: 10 µm.
3.2. Downregulation of DDX11 Severely Alters the Morphology and Disrupts the Segregation of
RCC Cells
We transfected 786-O cells with a previously reported DDX11-specific siRNA [12,15].
Imaging was performed 24 h after transfection to ascertain the effective uptake of the
DDX11-specific siRNA, and the results revealed the presence of DDX11-specific siRNA in
RCC cells (Figure 3A).
The levels of DDX11 decreased following the transfection of 786-O RCC cells with
DDX11 siRNA (25 nM) compared to those in the control (786-O cells transfected with 25 nM
of a pool of siRNAs comprising four non-targeting siRNAs). qPCR analysis 48 h after
transfection revealed that the expression of DDX11 decreased in 786-O cells transfected with
DDX11-specific siRNA compared to that in 786-O cells that had only received Lipofectamine
RNAiMAX or the control siRNA pool (Figure 3B; p = 0.0091).
RCC cells transfected with the DDX11 siRNA exhibited a rapid and dramatic alteration
in their morphology compared to the control siRNA-transfected cells (Figure 3C, panel a).
In particular, we found that DDX11 siRNA transfection caused RCC cells to lose cell-cell
contact in as little as 24 h and at doses of 25 nM and 50 nM. Moreover, a significant number
of transfected RCC cells exhibited a tightly arranged chain-like morphology (Figure 3C,
panels b and c).
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Figure 3. Analysis of DDX11 small interfering (si) RNA-transfected renal cell carcinoma cells.
(A) Immunofluorescence to investigate DDX11 expression in 786-O cells 24 h following transfection
with 5 nM of Cy5-conjugated DDX11 siRNA; DDX11 (pseudocolored red), nuclei (pseudocolored
blue), Scale bar: 50 µm. (B) Quantitative PCR investigating the expression of DDX11 in 786-O cells
that received only Lipofectamine (black-colored filled bar) or were transfected with 25 nM of control
siRNAs (gray-colored filled bar) or DDX11 siRNA (red-colored filled bar) for 48 h (* denotes p value
less than 0.05). (C) Phase-contrast images, captured at 20× magnification, depicting the morphology
of 786-O cells following transfection with 50 nM of control siRNAs for 96 h (a) or with 25 nM (b) or
50 nM (c) of DDX11 siRNA for 24 h. The red-colored arrow in the phase-contrast images, shown in
panels b and c, points to the chain-like morphology of 786-O cells that did not separate, Scale bar:
200 µm (upper row), 100 µm (lower row).
3.3. DDX11 Knockdown Severely Inhibits RCC Cell Proliferation and Induces Apoptosis of
RCC Cells
We transfected RCC cells (5000 cells/96-well plate) with 25 nM each of DDX11 or the
pool of control siRNAs; the rates of cell proliferation were measured 24 h after transfection
and every 24 h thereafter. As shown in Figure 4A, compared to RCC cells that had received
only Lipofectamine RNAiMAX or were transfected with the control siRNAs, RCC cells
transfected with DDX11-specific siRNA exhibited strongly inhibited proliferation even up
to 72 h post-transfection (p = 0.003).
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Figure 4. DDX11 knockdown in renal cell carcinoma cells resulted in the inhibition of proliferation and apoptosis. (A) Prolif-
eration of 786-O cells that received only Lipofectamine (black-colored line) or were transfected with 25 nM of control siRNAs
(gray-colored line) or 25 nM of DDX11 siRNA (red-colored line). The value at each time point following siRNA transfection
is the mean of triplicate samples analyzed (* denotes p value with 0.003). (B) Apoptosis of 786-O cells transfected for 48 h
with 50 nM of control siRNAs (a) or 50 nM of DDX11 siRNA (b) was analyzed using the TUNEL assay; TUNEL-positive
cells (pseudocolored red), nuclei (pseudocolored blue), scale bar: 100 µm. Apoptosis of 786-O cells transfected for 48 h with
50 nM of control siRNAs (a) or 50 nM of DDX11 siRNA (b) was analyzed using the TUNEL assay.
The most severe DDX11 siRNA-induced change was that the cells rapidly and mas-
sively underwent apoptosis, as demonstrated by the terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) assay. RCC cells that had been transfected
for 48 h with 50 nM of the pooled siRNA did not reveal any apoptosis, but RCC cells
transfected with DDX11 siRNA clearly exhibited apoptosis with significance (p < 0.001)
(Figure 4B).
3.4. DDX11 Knockdown in RCC Cells Induces Sensitivity to PARP Inhibition
RCC cells transfected with DDX11 siRNA or control siRNA were treated with a
clinically approved PARP inhibitor, olaparib; subsequently, cell proliferation was evaluated
to investigate the association between DDX11 expression and the sensitivity to PARP
inhibition. In response to treatment with olaparib alone, DDX11 siRNA-transfected RCC
cells exhibited decreased viability (starting from 48 h) compared to those transfected
with the control siRNAs and mostly showed significant differences (p < 0.001; 72 h time
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point). Thus, RCC cells with DDX11 knockdown exhibited increased sensitivity to olaparib
(Figure 5A).
Figure 5. DDX11 knockdown in renal cell carcinoma cells induced sensitivity to poly (ADP-ribose) polymerase (PARP)
inhibitors. (A) Proliferation curves of 786-O cells transfected with the control siRNAs or DDX11 siRNA following olaparib
treatment after 24, 48, and 72 h. (B) Cell viability after exposure to sunitinib, olaparib, or a combination of both drugs
in the background of transfection with DDX11 siRNA or control siRNA for 48 h (ns, not significant). (C) Proliferation
curves of 786-O cells transfected with the control siRNAs or with the DDX11 siRNA after 24, 48, and 72 h of sunitinib or
olaparib treatment.
Furthermore, viability was evaluated upon exposure of RCC cells to sunitinib, olaparib,
or both drugs in combination with DDX11 siRNA transfection or with control siRNA
transfection. As shown in Figure 5B, a significant difference (p = 0.010, 48 h time point)
in cell viability was observed following olaparib treatment; however, no differences were
observed when the cells were treated with sunitinib alone or with a combination of sunitinib
and olaparib. Proliferation curves revealed that the efficacy of olaparib was similar to
that of sunitinib in RCC cells transfected with DDX11 siRNA. Furthermore, when DDX11
was knocked down, olaparib exerted effects similar to those of sunitinib (Figure 5C).
For comparison of the efficacy of other PARP inhibitors on DDX11 siRNA transfected
cells, veliparib was used. Veliparib demonstrated efficacy similar to olaparib in DDX11
knockdown RCC cells (p < 0.001; 72 h time point, Supplementary Figure S3A). Moreover, a
significant difference (p = 0.019, 48 h time point) in cell viability was only observed between
groups with DDX11 siRNA transfection or with control siRNA transfection following
veliparib treatment (Supplementary Figure S3B).
3.5. DDX11 Knockdown in RCC Cells Increases PARP Protein Expressions in Nucleus
RCC cells transfected with DDX11 siRNA or control siRNA were treated with a
clinically approved PARP inhibitor, olaparib; subsequently, immunofluorescence staining
of PARP was performed to measure and investigate the increased PARP expression in
nuclei of DDX11 knockdown RCC cells. PARP expression was increased in DDX11 siRNA-
transfected RCC cells compared to control siRNA-transfected cells. In response to treatment
with olaparib, PARP expression was decreased both in RCC cells with DDX11 siRNA
transfection or with control siRNA transfection (Supplementary Figure S4).
Cancers 2021, 13, 2574 10 of 15
4. Discussion
This is the first study to demonstrate that the expression of the DEAD/DEAH box
helicase, DDX11, is upregulated during progression from early to advanced ccRCC. Our
findings revealed the important role played by DDX11 in preventing chromosomal segre-
gation and apoptosis in advanced ccRCC cells, thereby maintaining the aggressiveness of
this cancer. Furthermore, the novel and important findings described herein reveal that
DDX11 is the determinant of PARP inhibitor sensitivity in RCC.
We focused on identifying biomarkers associated with the progression of localized
low-grade ccRCC to advanced high-grade ccRCC. We identified 10 genes in samples
isolated from archived, formalin-fixed, and paraffin-embedded tissue samples representing
aggressive ccRCC with synchronous metastasis, recurrence, or cancer-specific death versus
those with non-aggressive ccRCC [9]. Our analysis revealed that the expression of DDX11—
a gene not known to be associated with ccRCC—was upregulated in aggressive ccRCC
compared to that in non-aggressive ccRCC, and that this upregulation was significantly
related to poor overall survival (p < 0.05) [9]. Furthermore, a prospective validation cohort
study (NCT03694912) involving 140 patients revealed that the levels of DDX11 mRNA in
tissues as well as in the plasma are significantly associated with high-grade ccRCC [10].
DDX11 (ChlR1), first isolated as the human homolog of the yeast CHL1 gene, is a
member of the DEAD/DEAH box family of helicases. It is required for the cohesion of
chromosomal arms and centromeres, thereby playing an important role in maintaining
genome stability [11,17–19]. The Pisani group and collaborators demonstrated that DDX11
functionally interacts with Timeless, a subunit of the replication-fork protection complex,
to preserve fork integrity [20], and recent study reported that DDX11 resolves problems
occurring at the replication forks [21]. Biochemical characterization of DDX11, produced
in recombinant form, revealed that it has an ATPase-dependent DNA unwinding activity
with a 5′ to 3′ directionality in vitro and is also able to dismantle unconventional DNA
structures [22–27]. However, to date, little is known regarding the role of helicases in
ccRCCs. DDX11 loss has been reported to result in alterations in telomeric chromatin
formation [19]. Furthermore, DDX11 interacts with the flap structure-specific endonuclease
1 (FEN-1) [24], an event that is pivotal to ensure telomere stability. Thus, similarly to
DDX39—which is associated with telomere lengthening [28]—DDX11 plays an important
role in maintaining telomere length and stability in malignancies such as melanoma, lung
cancer, and RCC [12,13]. Bhattacharya et al. [12] reported that high DDX11 expression was
significantly associated with poor prognosis in advanced melanomas. Moreover, similarly
to the findings observed in this study, Li et al. [13] reported that DDX11 was significantly
upregulated and predicted poor prognosis in lung adenocarcinoma. Besides melanoma
and lung cancer, associations with hepatocellular carcinoma (HCC) and osteosarcoma have
been reported [22]. Two recent studies have reported the association of DDX11 in HCC
development and progression [29,30]. Yu et al. suggested a pro-tumorigenic role of DDX11
in xenograft cancer animal models and demonstrated that DDX11 overexpression leads to
activation of PI3K/AKT/mTOR signaling pathway [29].
Here, we have shown that the inhibition of DDX11 results in rapid RCC cell apop-
tosis. Although this finding has been reported in studies on DDX11-/- mice, which
show that DDX11 depletion induces apoptosis [31,32], no other studies—except those
on melanoma [12]—have shown that rapid programmed cell death is induced in response
to DDX11 downregulation.
Numerous efforts have been made to improve the survival of patients with metastatic
RCC (mRCC), and enhanced survival has been clearly documented in this era of targeted
therapies and immunotherapies [4,6]. The currently available mRCC-targeted therapies
include vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors, anti-VEGF
monoclonal antibodies, and mammalian target of rapamycin inhibitors [4,6]. Contrary to
traditional immunotherapies, such as interferon-α and interleukin 2, which are associated
with excessive toxicity, modern immunotherapies, such as antibodies against programmed
cell death protein 1, programmed death-ligand 1, or cytotoxic T-lymphocyte-associated
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protein 4, disable the ability of tumor cells to evade the immune system without any
significant side effects [33–35]. Currently, 15 different therapeutic approaches, 10 agents
for first-line treatment, and 11 agents for further-line treatment have been approved for
mRCC [36].
However, despite these improvements and increased therapeutic options, the selection
of treatments for individual patients is becoming more challenging. This is because of
an apparent paradox in modern oncology: the targeted treatments are employed without
assessing the genomic profile of the tumors in individual patients [4,6]. Several studies
have identified and incorporated gene expression signatures and mutation status into the
decision-making protocol regarding treatment [7,37,38]. PBRM1 mutation is associated
with favorable responses to antiangiogenic therapies [37,38], while BAP1 mutation is
associated with poor response to antiangiogenics due to reduced angiogenic signaling [37].
However, at present, molecular profiling is not performed in routine clinical settings to
enable personalized treatment [6]. Therefore, we focused on identifying clinically useful
biomarkers that would guide the selection of treatment options.
“BRCAness” is a term used to describe tumors with a defect in DNA double-strand
break repair by homologous recombination, which mimic defects in BRCA [39–41]. The
positive response of BRCA-mutated breast and ovarian cancers to PARP inhibitors [42,43]
has raised interest in identifying additional determinants of PARP inhibitor sensitivity,
thereby extending the utility of PARP inhibitors in cancer therapy [39]. However, the use of
PARP inhibitors has not been approved for the treatment of mRCC, and only a few clinical
trials (e.g., NCT03786796) are investigating the effects of the PARP inhibitors on mRCC.
Only one in vitro study has suggested the possible use of PARP inhibitors for RCCs [39].
Scanlon et al. [39] demonstrated that von Hippel–Lindau (VHL) deficiency—present in
60–80% of ccRCC patients—is associated with increased sensitivity to PARP inhibitors.
Similarly, our study demonstrated that decreased DDX11 expression in RCC increases
the sensitivity to PARP inhibitors, indicating that DDX11-deficient RCCs share some
features with BRCAness tumors. Furthermore, our study is the first to report the increased
PARP expression in nuclei of DDX11-deficient RCC cells, demonstrating that DDX11
downregulation renders RCCs sensitive to PARP inhibitor and that DDX11 is involved in
the repair of PARP trapping. DDX11-depleted RCC cells were more vulnerable to olaparib
than to sunitinib alone or to a combination of sunitinib plus olaparib. Moreover, we have
reported that olaparib and sunitinib exhibited similar efficacies against DDX11-deficient
RCC cells; this result is novel because PARP inhibitors have not been recommended for the
treatment of RCC to date. Therefore, investigations of PARP inhibitors in DDX11-deficient
RCC animal models must be performed to enable future clinical applications.
A possible mechanism that could explain the increased PARP inhibitor sensitivity
in DDX11-deficient RCC cells is the involvement of DDX11 in sister chromatid cohesion
during replication in the S phase [44]. The replication fork protection complex stabilizes
DDX11, leading to the stable association of the cohesion complex with chromatin [15].
Moreover, DDX11 enhances the activity of FEN1, which is involved in lagging-strand DNA
synthesis [24]. As the depletion of FEN1 results in the development of cohesion defects, and
FEN1-deficient cells are sensitive to PARP inhibitors [24,45], we inferred that lagging-strand
synthesis might be crucial for sister chromatid cohesion. In summary, DDX11 deficiency
results in the development of defects in sister chromatid cohesion and lagging-strand DNA
synthesis, thereby comprehensively increasing PARP inhibitor sensitivity.
We used the 786-O cell line for our analysis because it harbors a mutated VHL [46,47]
with altered hypoxia-inducible factor 1 and VEGF pathways. As demonstrated in a previous
study, VHL-deficient renal cells and VHL-deficient RCC tissue samples exhibit reduced
expression of homologous recombination- and mismatch repair-related genes, and increased
sensitivity to PARP inhibitor [39]. Our study showed that VHL-deficient 786-O cells became
more susceptible to the PARP inhibitor olaparib in the background of DDX11 downregulation.
Because DDX11 is a nuclear protein, our results showed clear localization of DDX11 in
the nucleus, especially during interphase, prophase, and metaphase. However, localization
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of DDX11 in the cytoplasm was also noted. This might be due to the dynamic localization
of DDX11 during mitosis [11,12]. Parish et al. [11] and Bhattacharya et al. [12] reported
dynamic localization of DDX11 during mitosis which is similar to our study. Further
investigations on why nuclear protein, DDX11, is becoming localized in cytoplasm during
mitosis should be performed.
There were a few limitations in this study. First, we could not clinically validate
the efficacy of olaparib in DDX11-deficient RCC patients. It would be more promising if
olaparib had demonstrated its superior efficacy in DDX11-overexpressed ccRCC compared
to DDX11-downexpressed ccRCC, because the use of olaparib would not be limited to
non-aggressive ccRCC patients, who have fewer options for targeted therapy compared to
those with aggressive ccRCC. However, no other studies have suggested the use of PARP
inhibitor in ccRCC. Therefore, this study has its significance in suggesting the use of PARP
inhibitor as an option for targeted therapy in ccRCC patients. Future clinical studies of
DDX11-deficient RCC patients who are refractory to conventional treatments and can be
treated with olaparib are planned to address this issue. Second, owing to limited funding
and time, we could not develop a DDX11-deficient xenograft model using CRISPR/Cas9.
Third, BRCA 1 and 2 could not be evaluated in this study due to the technical difficulty
and lack of previous studies reporting an association of BRCA 1 and 2 with RCC [40,41].
Therefore, the evaluation and knockdown of BRCA 1 and 2 ranks as an independent
theme for large studies to be performed in the future. Fourth, we demonstrated that PARP
expression was increased in the nucleus after DDX11 knockdown, despite the unknown
association with chromatin. Demonstration of PARP retention on chromatin would be
better presented with the method used in the study by Muari et al. [45]; that approach
will be incorporated in a future study. Despite its weaknesses, our study is the first to
demonstrate the role of DDX11 in ccRCC and the use of PARP inhibitors for treatment of
DDX11-deficient ccRCC.
5. Conclusions
To the best of our knowledge, this is the first study to demonstrate that DDX11 is
expressed at high levels in advanced RCC, but not in normal kidney tissues or benign renal
tumors. Furthermore, we found that the downregulation of DDX11 induced segregation
defects, inhibition of cell proliferation, and rapid RCC cell apoptosis. Finally, we identi-
fied determinants of PARP inhibitor sensitivity in RCC, which have not been previously
reported. Collectively, these results suggest that DDX11 represents a new therapeutic
biomarker for the treatment of mRCC that is refractory to conventional targeted therapies
and immunotherapies.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/cancers13112574/s1, Figure S1: Immunoblot representing the expression of DDX11 in RCC cells
transfected with 3 different DDX11-targeting siRNAs (DDX11 siRNA #1, custom-synthesized DDX11
siRNA (Dharmacon); DDX11 siRNA #2, SMARTpool ON-TARGETplus DDX11 siRNA (Dharmacon);
DDX11 siRNA #3, Silencer Select DDX11 siRNA (Thermo Fisher Scientific)). β-actin was used as
the internal control, Figure S2: (A) PARP inhibitor sensitivity of 786-O cells that transfected with
control siRNAs (black-colored line) or DDX11 siRNA (red-colored line) treated with increasing
concentrations of olaparib. (B) PARP inhibitor sensitivity of 786-O cells that transfected with control
siRNAs (black-colored line) or DDX11 siRNA (red-colored line) treated with increasing concentrations
of veliparib, Figure S3: (A) Proliferation curves of 786-O cells transfected with the control siRNAs or
DDX11 siRNA following veliparib treatment after 24, 48, and 72 h. (B) Cell viability after exposure to
sunitinib, veliparib, or a combination of both drugs in the background of transfection with DDX11
siRNA or control siRNA for 48 h, Figure S4: 786-O cells that transfected with control siRNA or
DDX11 siRNA treated with olaparib for 24 h followed by staining against PARP. Representative
immunofluorescence staining image of PARP (pseudocolored green) and DAPI (pseudocolored blue),
Scale bar: 10 µm. Figure S5: Original Western Blots.
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